126 studies found for:    Immunodeficiency NOT AIDS | Open Studies
Show Display Options
Rank Status Study
21 Recruiting Sirolimus Prophylaxis for aGVHD in TME SCID
Conditions: Severe Combined Immunodeficiency;   Transplacental Maternal Engraftment;   Stem Cell Transplant
Intervention: Drug: Sirolimus
22 Recruiting Study of Safety, Tolerability, and Efficacy of Ustekinumab for Symptomatic Gastrointestinal Inflammation Associated With Common Variable Immunodeficiency
Conditions: CVID;   Enteropathy;   Chronic Diarrhea;   Maldigestion;   Malabsorption
Intervention: Biological: Ustekinumab
23 Recruiting The Rifaximin Study in CVID
Condition: Common Variable Immunodeficiency (CVID)
Intervention: Drug: Rifaximin
24 Recruiting CD34+ Stem Cell Infusion to Augment Graft Function
Conditions: Waning Donor Chimerism;   Waning Immune Function;   Primary Immunodeficiency Disease(s);   Bone Marrow Failure
Intervention: Biological: CD34+
25 Recruiting Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed By a Donor Stem Cell Transplant in Treating Patients With Immunodeficiency or Other Nonmalignant Inherited Disorders
Condition: Precancerous Condition
Interventions: Biological: alemtuzumab;   Drug: fludarabine phosphate;   Radiation: total-body irradiation;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Procedure: allogeneic bone marrow transplantation;   Procedure: allogeneic hematopoietic stem cell transplantation;   Other: laboratory biomarker analysis
26 Recruiting Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed By Donor Bone Marrow Transplant, Cyclophosphamide, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Immunodeficiency or Noncancerous Inherited Disorders
Conditions: Aplastic Anemia;   Nonneoplastic Condition
Interventions: Drug: cyclophosphamide;   Radiation: total-body irradiation;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Drug: tacrolimus;   Procedure: allogeneic bone marrow transplantation;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Other: laboratory biomarker analysis
27 Recruiting Sequential Cadaveric Lung and Bone Marrow Transplant for Immune Deficiency Diseases
Conditions: Severe Combined Immunodeficiency (SCID);   Immunodeficiency With Predominant T-cell Defect, Unspecified;   Severe Chronic Neutropenia;   Chronic Granulomatous Disease (CGD);   Hyper IgE Syndromes;   Hyper IgM Deficiencies;   Wiskott-Aldrich Syndrome;   Mendelian Susceptibility to Mycobacterial Disease;   Common Variable Immune Deficiency (CVID)
Intervention: Biological: CD3/CD19 negative allogeneic hematopoietic stem cells
28 Unknown  Evaluation of Efficacy and Tolerability of Hizentra®
Condition: Primary Immunodeficiency Disorders
Intervention: Drug: Hizentra
29 Recruiting Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies
Conditions: SCID;   Omenn's Syndrome;   Reticular Dysgenesis;   Wiskott-Aldrich Syndrome;   Bare Lymphocyte Syndrome;   Common Variable Immunodeficiency;   Chronic Granulomatous Disease;   CD40 Ligand Deficiency;   Hyper IgM Syndrome;   X-linked Lymphoproliferative Disease;   Hemophagocytic Lymphohistiocytosis;   Griscelli Syndrome;   Chediak-Higashi Syndrome;   Langerhan's Cell Histiocytosis
Interventions: Drug: Alemtuzumab 0.3 mg;   Drug: Cyclophosphamide;   Drug: Busulfan;   Biological: Stem Cell Transplantation;   Drug: Fludarabine phosphate 40 mg;   Drug: Melphalan;   Drug: Alemtuzumab 0.2 mg;   Drug: Fludarabine phosphate 30 mg;   Drug: MESNA
30 Recruiting Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations
Conditions: GATA2;   Immunodeficiency;   MDS
Interventions: Drug: Fludarabine(Fludara, Berlex Laboratories);   Drug: Busulfan (Busulfex);   Drug: Cyclophosphamide(CTX, Cytoxan);   Procedure: Total Body Irradiation (TBI);   Drug: Equine Anti-Thymocyte Globulin
31 Recruiting Study of Octanorm Subcutaneous IG in Patients With PID
Condition: Primary Immune Deficiency Disorder
Intervention: Biological: octanorm 16.5%
32 Recruiting Immune Disorder HSCT Protocol
Conditions: Immune Deficiency Disorders:;   Severe Combined Immunodeficiency;   Chronic Granulomatous Disease;   X-linked Agammaglobulinemia;   Wiskott-Aldrich Syndrome;   Hyper-IgM;   DiGeorge Syndrome;   Chediak-Higashi Syndrome;   Common Variable Immune Deficiency;   Immune Dysregulatory Disorder:;   Hemophagocytic Lymphohistiocytosis;   IPEX;   Autoimmune Lymphoproliferative Syndrome;   X-linked Lymphoproliferative Syndrome
Intervention: Drug: Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan
33 Recruiting Assessment of the Biochemical Response to Interferon-Gamma in Subjects With Specific Gene Mutation in Chronic Granulomatous Disease
Conditions: IFN-Gamma Therapy;   CGD Gene Mutation;   CGD Response to IFNg;   Chronic Granulomatous Disease;   Immunodeficiency Disease
Intervention: Drug: IFN-gamma
34 Recruiting Evaluation of High Throughput Sequencing for Screening of Pathogens in Immunocompromised Patients With Suspected Infectious Disease.
Condition: Immunodeficiency and Suspected Infection
Intervention: Procedure: Blood sampling / Body fluid sampling
35 Not yet recruiting Lentiviral Gene Therapy for Adenosine Deaminase (ADA) Deficiency
Conditions: Adenosine Deaminase Deficiency;   Severe Combined Immunodeficiencies (SCID)
Intervention: Genetic: EF1αS-ADA lentiviral vector transduced patient Cd34+ cells
36 Recruiting Quality of Life and Neuropsychiatric Sequelae in Patients Treated With Gene Therapy for ADA-SCID and in Their Parents
Condition: ADA-SCID
Intervention:
37 Recruiting Detection and Characterization of Host Defense Defects
Conditions: Immunologic Deficiency Syndrome;   Infection
Intervention:
38 Recruiting Octagam 5% Versus Comparator Post Marketing Trial
Condition: Primary Immune Deficiency Disorder
Interventions: Biological: Octagam 5%;   Biological: Other marketed IVIG product
39 Recruiting Reduced Intensity Conditioning in Patients Aged ≤30 With Non-Malignant Disorders Undergoing Cord Blood Transplantation
Conditions: Primary Immunodeficiency Syndromes;   Congenital Bone Marrow Failure Syndromes;   Inherited Metabolic Disorders (IMD);   Hereditary Anemias;   Patients With Sickle Disease Presenting Specific Symptoms
Interventions: Drug: Hydroxyurea;   Drug: Alemtuzumab;   Drug: Fludarabine;   Drug: Melphalan;   Drug: Thiotepa
40 Recruiting Reduced Intensity Conditioning (RIC) Regimen for Patients With Non-malignant Disorders
Conditions: Non Malignant Diseases;   Immunodeficiencies;   Hemoglobinopathies
Intervention: Other: Hematopoetic Stem Cell Transplant using Reduced Intensity Conditioning Regimen

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
Indicates status has not been verified in more than two years